Literature DB >> 23009730

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).

Ronald N Jones1, Helio S Sader, Rodrigo E Mendes, Robert K Flamm.   

Abstract

A 14-year longitudinal survey of Streptococcus pneumoniae (18,911) strains by the SENTRY Antimicrobial Surveillance Program shows significant increases in resistance to amoxicillin/clavulanate (18.9%), penicillin at a MIC of ≥ 4 μg/mL (14.8%), and ceftriaxone (11.7%) among 2011 isolates. Fluoroquinolones (levofloxacin; 98.8% susceptible) and ceftaroline (99.1-100.0% susceptible depending on breakpoint criteria) exhibited high levels of potency, as did linezolid, tigecycline, and vancomycin (100.0%). In summary, resistance rates to several antimicrobials continue to rise after introductions of both pneumococcal conjugate vaccines, as noted from these results for 1998 through 2011.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009730     DOI: 10.1016/j.diagmicrobio.2012.08.024

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  27 in total

1.  Antimicrobial stewardship in daily practice: Managing an important resource.

Authors:  Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

2.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 3.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

4.  Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Authors:  Catharine C Bulik; Ólanrewaju O Okusanya; Elizabeth A Lakota; Alan Forrest; Sujata M Bhavnani; Jennifer L Hoover; David R Andes; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era.

Authors:  Sevgen Tanır Basaranoglu; Eda Karadag Oncel; Kubra Aykac; Yasemin Ozsurekci; Ali Bülent Cengiz; Ates Kara; Mehmet Ceyhan
Journal:  Hum Vaccin Immunother       Date:  2016-12-01       Impact factor: 3.452

6.  Antimicrobial stewardship in daily practice: Managing an important resource.

Authors:  Nicole Le Saux
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471

Review 7.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

8.  Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Authors:  David Oldach; Kay Clark; Jennifer Schranz; Anita Das; J Carl Craft; Drusilla Scott; Brian D Jamieson; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

9.  In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Authors:  Michael A Pfaller; Rodrigo E Mendes; Leonard R Duncan; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

10.  In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Authors:  R K Flamm; P R Rhomberg; H S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.